These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 28724168)

  • 21. Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
    Mabilleau G; Pereira M; Chenu C
    J Endocrinol; 2018 Jan; 236(1):R29-R42. PubMed ID: 28855317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incretins and cardiovascular disease: to the heart of type 2 diabetes?
    Solini A; Tricò D; Del Prato S
    Diabetologia; 2023 Oct; 66(10):1820-1831. PubMed ID: 37542009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials.
    Cao C; Yang S; Zhou Z
    Endocrine; 2019 Nov; 66(2):157-165. PubMed ID: 31420784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
    Busch RS; Kane MP
    Postgrad Med; 2017 Sep; 129(7):686-697. PubMed ID: 28657399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
    Barritt AS; Marshman E; Noureddin M
    Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
    Hayat J; Shah NP; Agarwala A; Khan MS; Butler J
    Curr Atheroscler Rep; 2024 Aug; 26(8):341-351. PubMed ID: 38809399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-Like Peptide-1 Receptor Agonists-Use in Clinical Practice.
    Tricò D; Solini A
    Adv Chronic Kidney Dis; 2021 Jul; 28(4):328-336. PubMed ID: 34922689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.
    Seksaria S; Dutta BJ; Kaur M; Gupta GD; Bodakhe SH; Singh A
    Curr Diabetes Rev; 2024; 20(6):e090823219597. PubMed ID: 37559236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.
    Heuvelman VD; Van Raalte DH; Smits MM
    Cardiovasc Res; 2020 Apr; 116(5):916-930. PubMed ID: 31825468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
    Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
    J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials.
    Varin EM; McLean BA; Lovshin JA
    Can J Diabetes; 2020 Feb; 44(1):68-77. PubMed ID: 31699625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
    Davis PN; Ndefo UA; Oliver A; Payton E
    Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GLP-1 receptor agonists in NAFLD.
    Petit JM; Vergès B
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GLP-1 receptor agonists and heart failure in diabetes.
    Scheen AJ
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S13-2S19. PubMed ID: 28431666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.
    Geloneze B; de Lima-Júnior JC; Velloso LA
    Drugs; 2017 Apr; 77(5):493-503. PubMed ID: 28233273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points.
    Yabe D; Kuwata H; Usui R; Kurose T; Seino Y
    Curr Med Res Opin; 2015; 31(7):1267-70. PubMed ID: 25916903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucagon-like peptide agonists: A prospective review.
    Mariam Z; Niazi SK
    Endocrinol Diabetes Metab; 2024 Jan; 7(1):e462. PubMed ID: 38093651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.